Johnson & Johnson EBIT

As of the most recent data (June 2026), JNJ shows a EBIT of $26B. That compares with $30B in the prior-year period — down 14.6% year over year. That is above the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, JNJ's EBIT is now $26B (was $30B) — a 14.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Johnson & Johnson is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. Johnson & Johnson is at $26B, which is higher that average. That is roughly 11.0% above the sector mean. Use the comparison chart on this page to see how JNJ stacks up against individual peers as well.

Tracking JNJ's ebit over time shows whether Johnson & Johnson is scaling, shrinking, or reshaping that part of the business. The current reading is $26B That compares with $30B in the prior-year period — down 14.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Johnson & Johnson's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $26B) with ownership activity and broader fundamentals.